"5-(2-amino-4-oxo-3-(2-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamide "

"5-(2-amino-4-oxo-3-(2-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamide " Suppliers list
Company Name: BOC Sciences  
Tel: 1-631-485-4226; 16314854226
Email: info@bocsci.com
Company Name: AN PharmaTech Co Ltd  
Tel: 86(21)68097365
Email: sales@anpharma.net
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com
Company Name: Shanghai Chaolan Chemical Technology Center  
Tel: QQ:65489617 13301690235
Email: Sales@ATKchemical.com
Company Name: Amadis Chemical Company Limited  
Tel: 571-89925085
Email: sales@amadischem.com
"5-(2-amino-4-oxo-3-(2-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamide " Basic information
Product Name:"5-(2-amino-4-oxo-3-(2-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamide "
Synonyms:"5-(2-amino-4-oxo-3-(2-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamide ";3-Pyridinesulfonamide, 5-[(3S)-2-amino-3,4-dihydro-4-oxo-3-[2-(trifluoromethyl)phenyl]-6-quinazolinyl]-N-(2,4-difluorophenyl)-2-methoxy-;5-(2-AMINO-4-OXO-3-(2-(TRIFLUOROMETHYL)PHENYL)-3,4-DIHYDROQUIZOLIN-6-YL)-N-(2,4-DIFLUOROPHENYL)-2-METHOXYPYRIDINE-3-SULFOMIDE;(3S)-GSK-F1;(3S)-GSK-F1, 10 mM in DMSO
CAS:1384097-27-1
MF:C27H18F5N5O4S
MW:603.52
EINECS:
Product Categories:
Mol File:1384097-27-1.mol
"5-(2-amino-4-oxo-3-(2-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamide " Chemical Properties
Safety Information
MSDS Information
"5-(2-amino-4-oxo-3-(2-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamide " Usage And Synthesis
Uses(S)-GSK-F1 (Compound 28) is an inhibitor for type III phosphatidylinositol 4-kinase α (PI4KIIIα). (S)-GSK-F1 inhibits PI4Kα, PI4Kβ, PI4Kγ, PI3Kα, PI3Kβ and PI3Kδ with pIC50 of 8.3, 6.0, 5.6, 5.6, 5.1 and 5.6, respectively. (S)-GSK-F1 exhibits anti-hepatitis C virus (HCV) activity through inhibition of HCV replication. (S)-GSK-F1 exhibits moderate pharmacokinetic characters in rat model[1].
IC 50PI4KIIIα: 8.3 (pIC50); PI4KIIIβ: 6.0 (pIC50); PI3Kα: 5.6 (pIC50); PI3Kδ: 5.6 (pIC50); PI3Kβ: 5.1 (pIC50)
References[1] Leivers AL, et al., Discovery of selective small molecule type III phosphatidylinositol 4-kinase alpha (PI4KIIIα) inhibitors as anti hepatitis C (HCV) agents. J Med Chem. 2014 Mar 13;57(5):2091-106. DOI:10.1021/jm400781h
"5-(2-amino-4-oxo-3-(2-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamide " Preparation Products And Raw materials
Tag:"5-(2-amino-4-oxo-3-(2-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamide "(1384097-27-1) Related Product Information
GSK-F1 "5-(2-amino-4-oxo-3-(2-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-6-yl)-N-(2,4-difluorophenyl)-2-methoxypyridine-3-sulfonamide " gamma-Glu-Cys trifluoroacetate salt Isorhamnetin LY 294002 Hydrochloride IPI-549